News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • President Trump ordered an immediate U.S. naval blockade of the Strait of Hormuz and vowed to interdict vessels paying Iran tolls, boosting oil-market risk.
  • Artemis II crew completed a successful splashdown, validating Orion heat-shield and recovery procedures and supporting aerospace contractor sentiment.
  • GSK reported early Mo-rez tumor shrinkage, with executives calling the asset a potential blockbuster for the company's oncology pipeline.
  • Credo fell after earnings despite blowout revenue and margins, creating a tactical buy window for momentum traders.
  • Analysts recommended a tactical long in UnitedHealth, citing Medicare Advantage rate tailwinds and Optum efficiency gains despite regulatory overhang.
  • Capital One is at an inflection; analysts advise a Hold while watching integration execution and rising credit signals.
  • CoreWeave triggered buy signals after multi-year deals and fresh financing, offering upside amid valuation and execution risk.

Latest Articles

Rothschild Redburn Lifts Church & Dwight to Neutral, Raises Target to $91

Rothschild Redburn Lifts Church & Dwight to Neutral, Raises Target to $91

Rothschild Redburn upgraded Church & Dwight Co. Inc. (NYSE: CHD) from Sell to Neutral and increased its price target to $91 from $81, citing a more constructive view on the consumer goods company's near-term outlook. The change follows an evaluation of past pricing actions, brand performance across the Power Brands portfolio, and broader sales tren…

China-Origin Drug Licensing Set to Surge Again as Pipeline Draws Global Buyers

China-Origin Drug Licensing Set to Surge Again as Pipeline Draws Global Buyers

Global pharmaceutical companies are accelerating purchases of China-developed experimental medicines as they aim to cut costs ahead of looming patent expirations. Licensing deal values tied to the greater China region jumped to an unprecedented $137.7 billion last year, and industry advisers say the total could grow substantially again over the nex…

Buy the Dip: Neurocrine Is More Than Ingrezza - A 180-Day Trade

Buy the Dip: Neurocrine Is More Than Ingrezza - A 180-Day Trade

Neurocrine (NBIX) sold off after below-expectation Ingrezza guidance, but the underlying business remains healthy: Ingrezza grew to $2.51B, Q4 sales topped $805.5M, and the company generates meaningful free cash flow. This trade idea buys the weakness with a clear stop and a 180-trading-day target that prices in recovery plus pipeline upside.

Citizens Lowers Upstart to Market Underperform, Assigns $20 Target

Citizens Lowers Upstart to Market Underperform, Assigns $20 Target

Citizens has downgraded Upstart Holdings Inc. from Market Perform to Market Underperform and established a $20.00 price target. The research house says the move is largely valuation-driven following the release of three-year medium-term guidance, and it highlights both marketwide pressure on fintech lenders with private credit exposure and mixed fo…

Swiss inflation holds at lower edge of SNB’s 0-2% band

Swiss inflation holds at lower edge of SNB’s 0-2% band

Switzerland’s headline inflation rate was unchanged at 0.1% in January, keeping it at the bottom of the Swiss National Bank’s 0-2% target range. Core inflation, which excludes fresh and seasonal food, energy and fuel, stood at 0.5%. Month-on-month consumer prices slipped 0.1%, driven by lower electricity costs and cheaper clothing and footwear. Eco…

Trump to Attend Saudi FII Forum in Miami as Riyadh Seeks Private Investment

Trump to Attend Saudi FII Forum in Miami as Riyadh Seeks Private Investment

U.S. President Donald Trump is expected to attend Saudi Arabia’s Future Investment Initiative (FII) conference in Miami from March 26-29, including a dinner hosted by Yasir Al-Rumayyan of the Public Investment Fund. His participation, a repeat since returning to the White House, comes as Saudi Arabia shifts its Vision 2030 strategy toward private c…

Dollar drifts ahead of US CPI; global FX markets brace for data

Dollar drifts ahead of US CPI; global FX markets brace for data

The U.S. dollar inched up on Friday but was largely constrained as markets awaited the January consumer price index, a key input for the Federal Reserve's rate outlook. The Dollar Index was slightly higher intraday yet poised for a roughly 0.6% weekly drop. Traders are watching for any upside surprises in inflation after a pattern of stronger-than-…

Heijmans posts robust 2025 results and issues upbeat 2026 guidance

Heijmans posts robust 2025 results and issues upbeat 2026 guidance

Heijmans delivered strong 2025 financial results, with group revenue rising 7.3% to €2.77 billion and adjusted EBITDA climbing 26.8% to €252 million. Net profit increased 44.4% to €130 million and the company raised its dividend to €2.37 per share. The order book expanded to €3.68 billion, and management provided optimistic 2026 guidance targeting …

Logistea Q4: Results Largely In Line; Board Proposes Higher Dividend

Logistea Q4: Results Largely In Line; Board Proposes Higher Dividend

Logistea reported fourth-quarter results that were broadly in line with market forecasts. Income from property management slightly exceeded consensus, net operating income matched expectations, and the company proposed a dividend above analyst forecasts. Modest property revaluations and a small dip in occupancy were offset by an improved cost of fi…

Jenoptik Sees 2026 as Return-to-Growth Year After Soft Q4 Orders

Jenoptik Sees 2026 as Return-to-Growth Year After Soft Q4 Orders

Jenoptik AG reported preliminary full-year 2025 sales of about €1.05 billion, a 6% decline year-over-year, and preliminary EBITDA of roughly €192 million, down 13% versus 2024. Fourth-quarter orders were weak, leaving the full-year book-to-bill at 0.95x and the Q4 book-to-bill at 0.75x. Management expects a return to revenue growth and margin impro…

Tietoevry Prioritizes Margin Gains as Revenue Outlook Remains Weak

Tietoevry Prioritizes Margin Gains as Revenue Outlook Remains Weak

Tietoevry has increased its 2026 cost-savings target and is focusing on margin improvement despite a soft top-line outlook. The company reported a 2% organic revenue decline in Q4 2025, significant progress on adjusted EBITA margin, and substantial headcount reductions. Management expects modestly negative to flat organic growth in 2026 but is aimi…